Regulatory Filings • Aug 26, 2014
Regulatory Filings
Open in ViewerOpens in native device viewer
BAGNEUX, France, August 26, 2014 - DBV Technologies, (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, today announced that the Company's management will be hosting investor meetings during the Goldman Sachs European Biotech Symposium to be held in London on Friday, September 5, 2014.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that is constantly increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studied in Phase II program.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 [email protected]
VP Finance, US Investor Relations & Strategy Tel. : +1 917-346-3447 [email protected]
Director, Corporate Communication & Business Development Tel. : +33(0)1 55 42 78 72 [email protected]
U.S. Investor Relations The Trout Group Tel. : +1 646-378-2926 [email protected]
Marion Janic Tel. : +1-212-223-4017 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.